Celera's Proteomics Program Focuses on Biomarker-Based Lung Cancer Test | GenomeWeb

By Adam Bonislawski

At the American Association for Cancer Research's annual meeting this month, Celera presented data on a protein biomarker diagnostic for lung cancer, drawing attention to the company's proteomics program after several years of keeping it largely in the background.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.